TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response

Journal of Neurology, Neurosurgery, and Psychiatry
Carlos López-GómezLaura Leyva

Abstract

We aimed to assess the effects of interferon β (IFNβ) treatment on the expression of the splice variants of the Tumour necrosis factor-Related Apoptosis Inducing Ligand (TRAIL) and its receptors in different cell subpopulations (CD14+, CD4+ and CD8+) from patients with multiple sclerosis (MS), and to determine whether this expression discriminated responders from non-responders to IFNβ therapy. We examined mRNA expression of the TRAIL and TRAIL receptors variants in patients with MS, at baseline and after one year of IFNβ therapy, according to responsiveness to this drug. Long-term therapy with IFNβ increased the expression of TRAIL-α in T cell subsets exclusively from responders and decreased the expression of the isoform 2 of TRAILR-2 in monocytes from responders as well as non-responders. Lower expression of TRAIL-α, and higher expression of TRAIL-β in monocytes and T cells, was found before the onset of IFNβ therapy in patients who will subsequently become responders. Baseline expression of TRAILR-1 was also significantly higher in monocytes and CD4+ T cells from responders. The present study shows that long-term IFNβ treatment has a direct influence on TRAIL-α and TRAILR-2 isoform 2 expression. Besides, receiver operating ...Continue Reading

References

Mar 7, 1998·Journal of Neurology, Neurosurgery, and Psychiatry·K P WandingerM Otto
Mar 29, 2000·Scandinavian Journal of Immunology·O HalaasT Espevik
Jul 13, 2000·Cell Death and Differentiation·U WendlingF Zipp
Oct 26, 2001·The Journal of Biological Chemistry·Chandan Kumar-SinhaArul M Chinnaiyan
Oct 23, 2002·Brain : a Journal of Neurology·Mariola MatysiakKrzysztof Selmaj
Dec 3, 2005·Multiple Sclerosis : Clinical and Laboratory Research·N ArbourJ P Antel
Jan 27, 2006·Annals of Neurology·Jordi RíoXavier Montalban
Feb 8, 2006·Multiple Sclerosis : Clinical and Laboratory Research·F GilliA Bertolotto
Aug 29, 2006·Biochemical and Biophysical Research Communications·Andreas KriegCsaba Mahotka
Dec 26, 2006·Journal of Neuroimmunology·Begoña OliverOscar Fernández
May 9, 2007·Frontiers in Bioscience : a Journal and Virtual Library·Orhan AktasFrauke Zipp
Nov 6, 2007·Frontiers in Bioscience : a Journal and Virtual Library·Amanda S SolisJames G Patton
Oct 31, 2008·Journal of Neuroimmunology·Sanna RintaIrina Elovaara
May 19, 2009·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Olaf HoffmannJoerg R Weber
Jun 23, 2009·Multiple Sclerosis : Clinical and Laboratory Research·J RíoX Montalbán
Oct 6, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Tokunori IkedaSatoru Senju
Nov 23, 2011·Proceedings of the National Academy of Sciences of the United States of America·Joana A ZulaAnette H H van Boxel-Dezaire
Apr 13, 2012·The Journal of Biological Chemistry·Christopher C ValleyJonathan N Sachs

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
PCR

Software Mentioned

Primer

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis